Most Read Articles
01 Jun 2015
New drug applications approved by US FDA as of 15 – 31 May 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16 - 31 December 2017)

31 Dec 2017

New drug applications approved by US FDA as of 16-31 December which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

RHOPRESSA

  • Active Ingredient(s): Netarsudil
  • Strength: 0.02%
  • Dosage Form: Solution; Opthalmic
  • Company: Aerie Pharmaceuticals Inc
  • Approval Date: December 18, 2017
  • Submission Classification: Type 1 - New Molecular Entity
  • Indication(s): Indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
  • Approved Label: 12/18/2017(PDF)

PREXXARTAN
  • Active Ingredient(s): Valsartan
  • Strength: 4mg/ml
  • Dosage Form: Solution;oral
  • Company: Carmel Biosciences Inc
  • Approval Date: December 19, 2017
  • Submission Classification: Type 3 - New Dosage Form
  • Indication(s): Indicated for 
    • Hypertension in adults and children six years and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
    • Heart failure (NYHA class II-IV); PREXXARTAN significantly reduces hospitalization for heart failure in patients who are unable to swallow valsartan tablets.
    • Stable left ventricular failure or left ventricular dysfunction following myocardial infarction; PREXXARTAN reduces cardiovascular mortality in patients who are unable to swallow valsartan tablets.
  • Approved Label: 12/19/2017(PDF)

STEGLATRO
  • Active Ingredient(s): Ertugliflozin
  • Strength: 5 mg,15 mg 
  • Dosage Form: Tablet; oral
  • Company: Merck Sharp Dohme
  • Approval Date: December 19, 2017
  • Submission Classification: Labeling
  • Indication(s): Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
  • Approved Label: 12/19/2017(PDF)

STEGLUJAN
  • Active Ingredient(s): Ertugliflozin; Sitagliptin
  • Strength: 500 mg; 100 mg, 15 mg;100 mg
  • Dosage Form: Tablet; oral
  • Company: Merck Sharp Dohme
  • Approval Date: December 19, 2017
  • Submission Classification: Type 1 - New Molecular Entity
  • Indication(s): Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both ertugliflozin and sitagliptin is appropriate.
  • Approved Label: 12/19/2017(PDF)

SEGLUROMET
  • Active Ingredient(s): Ertugliflozin; Metformin Hydrochloride
  • Strength: 2.5 mg; 500 mg, 2.5 mg; 1000 mg, 7.5 mg; 500 mg, 7.5 mg; 1000 mg
  • Dosage Form: Tablet; oral
  • Company: Merck Sharp Dohme
  • Approval Date: December 19, 2017
  • Submission Classification: Labeling
  • Indication(s): Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are not adequately controlled on a regimen containing ertugliflozin or metformin, or in patients who are already treated with both ertugliflozin and metformin. 
  • Approved Label: 12/19/2017(PDF)

MACRILEN
  • Active Ingredient(s): Macimorelin
  • Strength: 0.5 mg
  • Dosage Form: Solution;oral
  • Company: Aeterna Zentaris GMBH
  • Approval Date: December 20, 2017
  • Submission Classification: Type 1 - New Molecular Entity
  • Indication(s): Indicated for the diagnosis of adult growth hormone deficiency
  • Approved Label: 12/20/2017(PDF)

SIKLOS
  • Active Ingredient(s): Hydroxyuera 
  • Strength: 100 mg, 1000 mg
  • Dosage Form: Tablet;oral
  • Company: Addmedica SAS
  • Approval Date: December 21, 2017
  • Submission Classification: Type 3 - New Dosage Form
  • Indication(s): Indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in pediatric patients, 2 years of age and older, with sickle cell anemia with recurrent moderate to severe painful crises. 
  • Approved Label: 12/21/2017(PDF)

GIAPREZA
  • Active Ingredient(s):Angiotensin II
  • Strength: 25 mg/ml
  • Dosage Form: Injectable; injection
  • Company: LA Jolla Pharmaceutical Co
  • Approval Date: December 21, 2017
  • Submission Classification: Type 1 - New Molecular Entity
  • Indication(s): Indicated to increase blood pressure in adults with septic or other distributive shock.
  • Approved Label: 12/21/2017(PDF)

LUMIFY
  • Active Ingredient(s): Brimonidine Tartrate
  • Strength: 0.025%
  • Dosage Form: Solution; Opthalmic
  • Company: Bausch & Lomb
  • Approval Date: December 22, 2017
  • Submission Classification: Type 5 - New Formulation or New Manufacturer
  • Indication(s): Indicated relieve redness of the eye due to minor eye irritations
  • Approved Label: 12/22/2017(PDF)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 Jun 2015
New drug applications approved by US FDA as of 15 – 31 May 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.